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Angiotensin II blockade delays progression of chronic kidney
disease by modifying intrarenal hemodynamics, but the
effects on metabolic adaptations are unknown. Using the
remnant kidney model of chronic kidney disease in rats, we
measured the effects of combined angiotensin II blockade
with captopril and losartan on renal oxygen consumption
(QO2) and factors influencing QO2. Remnant kidneys had
proteinuria and reductions in the glomerular filtration rate
(GFR), renal blood flow (RBF) and nitric oxide synthase-1
protein expression while QO2, factored by sodium
reabsorption (QO2/TNa), was markedly increased. Combined
blockade treatment normalized these parameters while
increasing sodium reabsorption but, since QO2 was
unchanged, QO2/TNa also normalized. Triple antihypertensive
therapy, to control blood pressure, and treatment with lysine,
to increase GFR and RBF, did not normalize QO2/TNa,
suggesting a specific effect of angiotensin II in elevating
QO2/TNa. Inhibition of nitric oxide synthase increased QO2 in
the kidney of sham-operated rats but not in the remnant
kidney of untreated rats. Our study shows that combined
captopril and losartan treatment normalized QO2/TNa and
functional nitric oxide activity in the remnant kidney
independent of blood pressure and GFR effects, suggesting
that other mechanisms in addition to hemodynamics underlie
the benefits of angiotensin II blockade.
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The kidney receives 20–25% of the cardiac output, and
becuase of its unique structure and physiology, it usually
borders of hypoxia. This is in part because of a preglomerular
oxygen diffusion shunt maintaining a low O2 tension (pO2)
in the cortex, around 40–45 mmHg1–3 and a relatively high
rate of oxygen consumption per gram tissue. In the normal
kidney, this high rate of oxygen consumption is primarily
obligated to sodium reabsorption (TNa) as the proximal
tubule primarily functions in an aerobic environment.
Therefore, kidney ischemia and hypoxia can be dictated not
only by adequacy of blood flow and supply of oxygen, but
also by changes in the rate of oxygen consumption. Varieties
of pathophysiological conditions are characterized by altera-
tions in the rate of kidney oxygen consumption. Hypoxia,
resulting from decreased oxygen supply or increased oxygen
consumption, can affect the expression of a wide array of
genes, including many fibrogenic factors, and has been
postulated as a common pathway to progressive chronic
kidney disease (CKD).4 Therefore, the regulation and
efficient utilization of O2 can be an important contributor
to the pathogenesis of progression of CKD.
Recent studies have suggested that renal oxygen con-
sumption (QO2) is regulated by nitric oxide (NO) and
angiotensin II (ANG II) in normal and diseased kidneys.
Acute nitric oxide synthase (NOS) inhibition, specifically of
NOS-1, or chronic ANG II infusion increases QO2 in normal
animals.5–7 There is evidence for increased oxygen consump-
tion in experimental models of hypertension and in early
diabetes. In the remnant kidney or 5/6th kidney ablation/
infarction (A/I) model, a traditional model of CKD, increased
QO2 per nephron or per sodium ion transported has also
been observed,8,9 along with indirect evidence of intrarenal
hypoxia.10 Moreover, evidence of intrarenal hypoxia is
evident before structural changes affecting the supply of
oxygen.11 Interestingly, the remnant kidney model shows
reduced renal expression of neuronal NOS and other
functional evidence of NO deficiency,12,13 whereas high
ANG II activity has been implicated, at least in the early
stages.14 Treatment of CKD with renin-angiotensin system
(RAS) blockers has been shown to delay the progression of
CKD,15–19 suggesting increased ANG II activity as one of the
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important factors contributing to the progression of CKD.
Although the beneficial effects of renin-angiotensin system
blockers on glomerular hemodynamics have been widely
published, the effects on renal metabolism have not received
enough attention.
In this study we tested the hypothesis that in A/I kidneys an
imbalance in the activities of NO and ANG II contributes to
increased oxygen consumption. We confirmed an increase in
oxygen consumption factored for TNa in the early stages of
remnant kidneys, and found a deficiency in NOS-1 protein
expression. We assessed the effects of ANG II inhibition on
oxygen consumption, and found that combined angiotensin-
converting enzyme inhibition and angiotensin type 1 (AT-1)
receptor blockade significantly decreased the elevated values for
oxygen consumption factored by TNa and markedly increased
renal blood flow (RBF) and glomerular filtration rate (GFR),
with restoration of NOS-1 protein expression, and demon-
strated that these beneficial metabolic effects of ANG II
blockade can be distinctly separated from the effect on systemic
blood pressure (BP) and the increase in filtered load.
RESULTS
Systolic blood pressure in conscious rats
Systolic blood pressure (SBP) was measured in three groups
of conscious rats by the tail-cuff method. As shown by
Figure 1, SBP significantly increased as early as day 4
following the A/I, and continued increasing, even more
rapidly, to day 7. This early BP rise was effectively prevented
by dual ANG II blockade. Triple therapy with hydralazine,
reserpine, and hydrochlorothiazide had the same antihyper-
tensive effect. Treatment of A/I rats with lysine had no impact
on SBP and values were similar to untreated remnant kidney
rats (Table 1).
Renal oxygen consumption and kidney function
Table 1 shows the means±s.e. for QO2, sodium transport
efficiency (QO2/TNa), GFR, RBF, mean arterial pressure
(BP), and urinary protein in the five groups of rats: (1) sham
operated, (2) untreated A/I, (3) A/I treated with dual ANG II
inhibition by captopril and losartan, (4) A/I with triple
antihypertensive therapy, and (5) A/I with lysine.
A/I rats had a lower RBF (4.25±0.34 vs 7.04±0.51 ml/
min, Po0.01) and a lower GFR (0.69±0.07 vs
1.14±0.13 ml/min, Po0.01), compared to shams, as ex-
pected with the marked reduction in nephron number. The
GFR was increased to normal values in the A/I rats treated
with ANG II inhibition, but not normalized by triple
antihypertensive therapy, suggesting a significant ANG II
association with renal hemodynamics in this early A/I model.
In the normal kidney, the major QO2 is used for TNa and the
ratio of QO2/TNa is relatively stable, which is around 1, as
shown with the sham group in Table 1. In spite of the
reduction in renal mass by about two-thirds, the A/I kidney
had a total QO2 similar to that of the sham kidney
(0.14±0.01 vs 0.16±0.01 ml/min, P40.05), suggesting that
the A/I kidney had an increased oxygen consumption per
nephron. This observation was further supported by a
substantially higher value of QO2/TNa (1.70±0.15 vs
1.00±0.12 ml/mol, Po0.05). The elevation in QO2/TNa
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Figure 1 | Changes of systolic blood pressure (SBP) in awake
A/I rats measured by tail-cuff method. Data are reported as
mean±s.e. Untreated A/I rats developed hypertension within 1
week. Both treatments significantly prevented the blood pressure
from rising. *Po0.05; **Po0.01 compared with baseline (day 0);
#Po0.01 compared with untreated A/I.
Table 1 | Renal oxygen consumption, transport efficiency, renal function, BP, and urinary protein in the five groups
Group QO2 (ml/min) QO2/TNa (M/M) GFR (ml/min) RBF (ml/min) BP (mmHg) Urinary protein
(1) Sham (n=7) 0.16±0.01 1.04±0.11 1.11±0.15 7.03±0.5 99±4 0  +
(2) A/I (n=20) 0.14±0.01 1.70±0.15 0.69±0.07 4.25±0.34 116±3 +++
Pvs I NS o0.05 o0.05 o0.01 o0.05
(3) A/I+T1 (n=19) 0.15±0.01 1.23±0.09 0.91±0.06 6.80±0.29 85±3 0  +
Pvs II NS o0.05 o0.05 o0.05 o0.01
(4) A/I+T2 (n=6) 0.14±0.01 1.54±0.12 0.76±0.09 4.7±0.40 85±7 +  ++
Pvs II NS NS NS NS o0.01
(5) A/I+T3 (n=6) 0.20±0.03 1.61±0.14 0.97±0.04 6.67±0.48 128±10
Pvs II o0.05 NS o0.01 o0.01 NS NA
Data are reported as mean±s.e.
A/I, renal ablation and infarction; BP, systemic blood pressure; GFR, glomerular filtration rate; QO2, renal oxygen consumption; QO2/TNa, sodium transport efficiency; RBF,
renal blood flow; TNa, transported sodium; T1, treatment with captopril and losartan; T2, treatment with hydralazine, reserpine and hydrochlorothiazide (triple therapy); T3,
treatment with lysine.
The urine was drawn directly from the bladder using a syringe right after anesthesia. The urinary protein concentration was detected using urinary 32 strips, where + stands
for trace to 0.3 mg/ml, ++ 1 mg/ml, and +++ 5 mg/ml.
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was reduced by ANG II inhibition (1.70±0.15 vs 1.23±0.09,
Po0.05), but not affected by the triple therapy (NS)
(1.54±0.12) suggesting that ANG II has a significant impact
on renal oxidative metabolism separate from effects on
systemic BP in this early A/I model. As shown in Table 1 and
Figure 2, both ANG II inhibition and lysine feeding
significantly increased GFR. However, the GFR increase by
lysine feeding was accompanied by a significant increase in
QO2 whereas the GFR increase by ANG II inhibition was
characterized by a constant QO2. Therefore QO2/TNa after
lysine was not different from untreated A/I rats and values
remained significantly higher that A/IþT1 rats. These
findings suggest that the increase in QO2 associated with
an increase in GFR was offset by a prevention of QO2
elevation caused by nontransport cellular processes in A/I
kidneys treated with ANG II blockade, implying that there
was an increased non Na-reabsorptive work requiring oxygen
in untreated A/I kidneys.
Effects of NOS blockade on renal oxygen consumption and
renal function in A/I kidneys
In this study of A/I kidney, which exhibits increased oxygen
consumption, we further tested if inhibition of NO
generation can induce additional increases in QO2 in early
stages of A/I kidney. NG-Monomethyl-L-arginine (L-NMMA)
was used for acute NO inhibition in four groups of rats: (1)
sham operated (Sham), (2) untreated A/I, (3) A/I treated
with dual ANG II inhibition by captopril and losartan
(A/IþT1), and (4) A/I with triple therapy by hydralazine,
reserpine, and hydrochlorothiazide (A/IþT2). As shown in
Table 2 and Figure 3, with respect to GFR, acute NOS
blockade with L-NMMA did not produce significant changes
in any of the four groups. However, acute NOS blockade
exerted different effects on QO2 in the four groups. NOS
blockade produced a significant increase in QO2 in the sham
group (0.16±0.01 vs 0.19±0.01, Po0.05) and no change in
QO2 in the untreated A/I group (0.12±0.01 vs 0.13±0.02,
P40.05), but there was a small and significant increase in
QO2/TNa in the untreated A/I kidney. NOS blockade
produced a significant increase in both QO2/TNa and QO2
in the A/I group treated with ANG II inhibition (0.13±0.01
vs 0.18±0.01, Po0.05) but produced no change in QO2/TNa
and QO2 in the A/I group treated with triple therapy
(0.14±0.01 vs 0.15±0.01, P40.05), suggesting that the NO
deficiency in this condition is related to ANG II and not just
increased BP.
Changes of NOS protein abundance in A/I kidneys
We determined NOS-1 protein abundance using the western
blot analysis in untreated A/I vs treated A/I, with the right
kidney as normal control. We chose NOS-1 as it has been
demonstrated by Szabo and Baylis that renal NOS-1 protein
expression is a marker of renal injury;20 and mitochondrial
NOS is believed to be of NOS-1 type.21,22 As shown in
Figure 4, the NOS-1 protein abundance in the renal cortex
was significantly reduced in A/I group, but was prevented by
dual ANG II blockade. However, NOS-1 protein expression
was also restored in the other A/I groups treated with triple
therapy and lysine. We, then, evaluated NOS-3 protein
expression to help explain the reduction in functional NO
activity in A/I kidneys and restoration of this activity by Ang
II blockade. NOS-3 was not different in sham and all A/I
kidney groups (Figure 5). Although NOS-2 expression was
different in the groups, it did not correlate with functional
NO activity either (unpublished observations).
DISCUSSION
This study confirms that the A/I kidney exhibits increased
oxygen consumption when factored by estimated remaining
nephrons or factored by total TNa (QO2/TNa) as observed by
others.8,9 ANG II inhibition with captoprilþ losartan nor-
malized this increase in QO2/TNa, suggesting a functional
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Figure 2 | Glomerular filtration rate, renal oxygen
consumption and sodium transport efficiency in rats on day 7
following A/I (renal ablation/infarction) surgery. T1, treatment
with dual ANG II inhibition (captopril 20 mg/kg/day and losartan
20 mg/kg/day); T3, treatment with L-lysine (0.5 g 2/rat/day). All
the drugs were given by daily gavage for 8 consecutive days.
*Po0.05 compared with sham; **Po0.05 compared with A/I. A/I
rats treated with lysine (T3) had an increased glomerular filtration
rate (GFR) and an increased total renal oxygen consumption (QO2)
with the sodium transport efficiency (QO2/TNa) remaining high. In
contrast, A/I rats treated with ANG II inhibition (T1) had an
increased GFR and unchanged QO2 with a normalized QO2/TNa.
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high ANG II state in the early stages of remnant kidney that
regulates oxygen utilization. We have further supplied
evidence that the effects of ANG II blockade on these
parameters are independent of their hemodynamic effects.
It has been traditional to factor QO2 by TNa because
studies have suggested that in the normal kidney approxi-
mately 80% of oxygen consumption is obligated to the
process of Na reabsorption, therefore generally linked to the
absolute values for GFR. As both QO2 and QO2/TNa are
increased in the untreated remnant kidney we should
summarize the elements that could contribute to this.
Oxygen requirements could increase because of either
acquired inefficiencies in the process of Na reabsorption or
shifts in the site of TNa to more distal tubular sites that
exhibit higher oxygen and adenosine triphosphate costs per
ion transported. Second, QO2/TNa and QO2 could be
increased due to effects on mitochondrial efficiency. An
example would be the effects of NO to reduce mitochondrial
oxygen consumption via effects on cytochrome c oxidase and
at other sites influencing oxidative metabolism. Finally, there
could be increases in ‘work’ other than Na reabsorption that
requires oxygen consumption either for adenosine tripho-
sphate requirements or increases in chemical utilization of
oxygen.
Table 2 | The effects of nitric oxide synthase blockade with L-NMMA on renal oxygen consumption, glomerular filtration rate,
ratio of oxygen consumption and sodium transport, and blood pressure in four groups
QO2 (ml/min) GFR (ml/min) QO2/TNa (M/M) BP (mmHg)
Group Basal L-NMMA Basal L-NMMA Basal L-NMMA Basal L-NMMA
Sham (n=7) 0.16±0.01 0.19±0.01* 1.11±0.15 0.94±0.08 1.04±0.11 1.54±0.16* 102±3 127±4**
A/I (n=10) 0.12±0.01 0.13±0.02 0.68±0.09 0.61±0.10 1.57±0.10 1.76±0.15* 115±12 151±11**
A/I+T1 (n=9) 0.13±0.01 0.18±0.01* 0.86±0.11 0.92±0.08 1.18±0.11 1.48±0.07* 80±3 103±3**
A/I+T2 (n=8) 0.14±0.01 0.15±0.01 0.76±0.09 0.87±0.12 1.40±0.13 1.29±0.08 85±7 113±11**
Data are reported as mean±s.e. *Po0.05 vs basal; **Po0.01 vs basal.
A/I, renal ablation and infarction; BP, systemic blood pressure; GFR, glomerular filtration rate; L-NMMA, NG-monomethyl-L-arginine, a nonselective nitric oxide synthase
inhibitor; QO2, renal oxygen consumption; T1, treatment with captopril and losartan; T2, treatment with hydralazine, reserpine and hydrochlorothiazide (triple therapy).
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Figure 3 | Changes of renal oxygen consumption in response
to acute nitric oxide synthase (NOS) inhibition in four groups.
Data are reported as mean±s.e. values on day 7 following A/I
surgery. A/I, untreated ablation/infarction; T1, dual ANG II
inhibition with captopril and losartan; T2, triple therapy with
hydralazine, reserpine, and hydrochlorothiazide. *Po0.05
compared with basal line. Acute superimposed NOS inhibition by
L-NMMA did not alter GFR in any group. The NOS inhibition
caused a significant increase in QO2 in the sham group, but this
response (increase in QO2) was not seen in untreated A/I rats. This
response to NOS inhibition was recovered by ANG II inhibition (T1)
but was not recovered by another antihypertensive treatment (T2).
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Figure 4 | . Western blot analysis of NOS-1 protein expressions
in renal cortex in the five groups of rats. (a) Representative
western blots showing the NOS-1 protein expression levels in
renal cortex from normal (CON), untreated renal ablation/
infarction (A/I), A/I with dual ANG II blockade (A/Iþ T1), A/I treated
with hydralazine, reserpine, and hydrochlorothiazide (A/Iþ T2)
and A/I treated with lysine (A/Iþ T3). (b) Summary graph
representing the relative abundance of NOS-1 protein levels in the
renal cortex analyzed using densitometry. There was a significant
reduction of NOS-1 protein expression in 1 week A/I cortex, and
this reduction was prevented not only by dual ANG II blockade
(T1) but by both T2 and T3. *Po0.01 (A/I vs CON); **Po0.01
(A/Iþ Tn vs A/I).
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In this study, ANG II blockade not only improved the
QO2/TNa but may have exerted other effects on the oxidative
status of the kidney. ANG II blockade normalized BP and also
produced a major increase in RBF and GFR. Therefore, we
generated another group in which BP was normalized using
triple therapy, a treatment that likely did not reduce kidney
ANG II activity. The QO2/TNa in this group remained
increased above values observed in captoprilþ losartan-
treated A/I kidneys, similar to values in the untreated A/I
remnant kidney. We addressed the second issue by increasing
GFR to a degree similar to that observed after combined
ANG II blockade by daily administration of lysine. Increasing
the GFR and RBF did not normalize QO2/TNa and duplicate
the effects of combined ANG II blockade. Therefore, these
two hemodynamic effects of ANG II blockade in the remnant
kidney rats did not contribute to the correction of QO2/TNa
achieved by captoprilþ losartan treatment.
The mechanisms whereby ANG II may increase kidney
QO2 have not been fully explained. There may be multiple
pathways involved, including stimulation of Na reabsorption.
However, this transport effect of ANG II does not necessarily
increase the QO2/TNa ratio or diminish the efficiency of Na
transport. Normal kidney also expresses nicotinamide
adenine dinucleotide phosphate (NADPH) oxidases,23 and
prolonged infusion of ANG II upregulates NADPH oxidase,
accompanied by an increase in renal QO2 and a decrease in
renal tissue oxygenation.7 Increased NADPH oxidase expres-
sion has been reported in rat kidneys 6 weeks after 5/6th
nephrectomy.24 ANG II also activates the enzyme systems;
lipooxygenases, cytochrome P-450, and cyclooxygenases,
producing a variety of bioactive molecules.25 However, it is
unlikely that ANG-II-stimulated oxidase activity would be
sufficient to explain the large increases in QO2 and QO2/TNa
in the untreated remnant kidney and the nearly complete
amelioration by ANG II blockade.
Extensive in vitro studies have demonstrated that NO is an
important regulator of oxygen utilization in mitochondria.
More than 85% of the oxygen utilized by the cell is consumed
by the mitochondrial electron transport system for adenosine
triphosphate synthesis. Most investigations have demon-
strated that NO and its derivatives inhibit mitochondrial
respiration in two different ways: (1) within the physiological
range, NO exerts an acute and reversible inhibition of
cytochrome c oxidase, in competition with O2, thereby
decreasing respiration,26–28 implying a ‘braking’ effect on
oxidative metabolism; and (2) at higher concentrations, NO
and its derivatives irreversibly inhibit multiple enzymes of the
mitochondria, including aconitase, complexes I, II, III, and
cytochrome b.29–33 Existence of mitochondrial NOS was
recently described in rat liver,34,35 brain,36 heart, and
kidney,37 and has been identified as the a-isoform of NOS-
1.21,38 The study by Laycock et al.6 demonstrated in vivo that
NO inhibition caused an increase in QO2 in normal
conscious dog. We have further clarified in a previous study
that the specific NOS-1 isoform inhibition leads to an
increase in oxygen consumption in normal rat kidney in vivo
and in isolated proximal tubules,5 the latter also demon-
strated by Koivisto and Persson.39
Various animal models of CKD are characterized by a
deficiency in NO generation and NOS-1 expression.12,13
Therefore, we examined the potential role of NO as an
intermediary that might explain the observed metabolic
effects of combined ANG II blockade. We have confirmed the
functional NO deficiency in the remnant kidney in the
current study, by demonstrating that in contrast to normal
kidneys, the untreated A/I kidney showed no change in
oxygen consumption in response to acute inhibition of NOS.
However, combined ANG II blockade restored the normal
response of kidneys to NOS blockade. To control for the
normalization of BP, we examined the effects of nonselective
NOS blockade in rats whose BP had been normalized by
triple therapy. These rats exhibited no increases in oxygen
consumption, similar to the untreated A/I kidneys. Protein
expression of NOS-1 was also reduced in untreated A/I, but
was restored in all A/I treatment groups. These results suggest
that the suppression of NOS-1 protein expression in the
untreated A/I kidney may derive from systemic and renal
hemodynamic consequences and/or changes in temporal
adaptation of the tubuloglomerular feedback system rather
than the consequence of increased ANG II activity. This
makes alteration in expression of NOS-1 an unlikely single
explanation for changes in NO activity or the cause of the
increase in oxygen consumption. This lack of correlation
between functional activity and protein expression of NO has
also been shown in the past to in conditions such as
variations in NaCl intake.40,41 Most importantly, the normal-
ization of the increase in QO2/TNa by ANG II blockade and
not other therapies in remnant kidneys did not correlate with
protein expression of NOS isoforms. The combination of
angiotensin-converting enzyme inhibitors and AT-1 receptor
blockers used in this study could have restored functional NO
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Figure 5 | Western blot analysis of NOS-3 protein expressions
in renal cortex in the five groups of rats. (a) Representative
western blots showing the NOS-1 protein expression levels in
renal cortex from normal (CON), untreated renal ablation/
infarction (A/I), A/I with dual ANG II blockade (A/Iþ T1), A/I treated
with hydralazine, reserpine and hydrochlorothiazide (A/Iþ T2),
and A/I treated with lysine (A/Iþ T3). (b) Summary graph
representing the relative abundance of NOS-1 protein levels in the
renal cortex analyzed using densitometry. There are no
differences in renal cortical NOS3 expression among five groups.
Kidney International (2009) 75, 197–204 201
A Deng et al.: Oxygen utilization in CKD o r i g i n a l a r t i c l e
activity by several potential mechanisms involving AT-1, AT-
2 receptors and elimination of NOS inhibitors that are
known to be elevated in this model.42–44 We also observed
that blockade of ANG II activity in the A/I kidney increased
RBF and GFR to a greater extent than expected in a normal
kidney, implying a greater ANG II impact in the A/I kidney.
Blockade of ANG II activity likely produced changes in
tubuloglomerular feedback activity potentially contributing
to this greater effect on GFR and RBF.
In the remnant kidney, hypoxia has been demonstrated by
indirect measurements in early10 and late stages, and has been
proposed as a final common pathway to progression of
CKD.4 However, the structural changes leading to a decrease
in blood supply implicated in the late stages cannot be
invoked to explain the hypoxia observed in the early stages.
An increase in demand or utilization of oxygen could also
contribute to hypoxia in the early stages. We have verified
previous observations in the remnant kidney of increased
oxygen consumption per remaining kidney mass or factored
by Na reabsorption in early stages,8,9 and this finding was
corrected with losartan and captopril treatment. ANG II
blockade also appeared to eliminate functional NO defi-
ciency. Early modification of hormonal status in the remnant
kidney model of CKD is critical to the regulation of oxygen
consumption and may prevent early hypoxia, thus suggesting
another important mechanism by which ANG II blockers
provide a salutary effect in progressive kidney diseases.
MATERIALS AND METHODS
Animal experiments described herein were conducted in accordance
with the NIH Guide for the Care and Use of Animals in Research.
Studies were conducted on male Wistar rats, weighing initially
between 220 and 250 g when purchased from Harlan (Indianapolis,
IN, USA).
Renal ablation and infarction surgery
The rats were anesthetized with sodium pentobarbital (50 mg/kg,
i.p.), and placed on temperature-controlled surgical table. Using
sterile precautions, the right kidney was exposed by a small right
flank incision. After separating the adrenal gland, the right renal
pedicle was ligated and the kidney was removed. A left flank incision
was then performed and the left kidney was retracted out of the
peritoneal space to expose the renal artery. Two branches of the left
renal artery were ligated with 3–0 silk sutures. The left kidney was
then gently retracted back into the body and the incision was closed.
Sham-operated rats underwent anesthesia and manipulation of the
renal pedicles on both sides, without removal of any renal mass. The
rats were kept warm until ambulatory.
BP measurement in awake rats
SBP of rats was measured by the tail-cuff method. Nonanesthetized
rats were placed in a plastic restraining holder mounted on a
thermostatically controlled warm plate that was maintained at 37 1C
during measurement. The tail protruded from the holder. A metal
tubular cuff, 7/16 inches, was placed around the tail of the rat. Cuff
inflation/deflation rates (25 mmHg/s) and maximum cuff pressure
(225 mmHg) were controlled by a programmed electro-sphygmo-
manometer PE-300 (Narco Bio Systems, Houston, TX, USA). The
reported values are the mean of 4–6 recordings performed at the
same time of day by the same investigator on 8 consecutive days
starting at 1 day before the A/I surgery. All the rats underwent
restraining holder training (15 min/per day) for 3–6 days.
Study groups and drug administration
Five groups of rats were used for the study: SHAM, sham-operated
rats; A/I, renal ablation/infarction; A/IþT1, A/I treated with
captopril (20 mg/kg/day) and losartan (20 mg/kg/day); A/IþT2,
A/I treated with hydralazine (20 mg/kg/day), reserpine (4.5 mg/kg/
day), and hydrochlorothiazide (10 mg/kg/day); and A/IþT3, A/I
treated with lysine (3 g/kg/day). All drugs were given by daily gavage.
The treatment started 1 day before the surgery and was continued
for 8 consecutive days.
Whole-kidney function and O2 consumption measurement
Clearance and O2 consumption experiments were performed as
described in details earlier.5
Briefly, 1 week after A/I, the rats were anesthetized with Inactin
(100 mg/kg, i.p.). After cannulation of trachea, left jugular vein, left
femoral artery and urinary bladder were catheterized. The left
kidney blood flow (RBF, ml/min) was monitored with a perivascular
ultrasonic transit time flow probe (Transonics T420; Ithaca, NY,
USA) connected to a computer for continuous recording. Proximal
left renal vein was used for sampling of venous blood. GFR (ml/min)
was 51 measured by clearance of 3H-inulin administered in Ringer’s
NaCl-NaHCO3 at 1.5 ml/h (10 mCi/ml). Blood samples were taken
from the femoral artery and renal vein for measurements of total
arterial blood hemoglobin (tHb), O2Hb, pO2, pCO2, pH, [Na
þ ],
[Kþ ], [HCO3
] with a color spectrophotometer, 682 CO-Oximeter
(Instrumentation Laboratory, Lexington, MA, USA). O2 content
(O2ct) was calculated by the formula:
O2ct ðml=ml bloodÞ ¼ ð1:39tHbO2Hb%
þ pO20:003Þ  100:
The total left kidney O2 consumption (QO2, ml/min) was calculated
from AV difference in O2 content multiplied by RBF. TNa is equal
to the total amount of sodium filtered (FNa) minus the amount of
sodium excreted in the urine (UNaV). After the surgical prepara-
tion, the animals were allowed 60 min for stabilization with the flow
probe in place and BP and RBF being recorded, after which
measurements were taken. L-NMMA (2 mmol/kg/min), a nonselec-
tive NOS inhibitor was administered intravenous infusion for
60 min in a group of rats.
Western blotting analysis
Renal medulla and cortex were homogenized (4 1C) in buffer
(25 mM Tris-HCl, pH 7.4, 0.5 mM ethylenediaminetetraacetic acid,
0.5 mM ethylene glycol tetraacetic acid, 10 mM b-mercaptoethanol,
50 mM b-glycerophosphate, 10 mM NaF, 1 mM Na3VO4) in the
presence of protease inhibitor cocktail (Roche, IN, USA). After
protein concentration measurement by Bradford method, the
homogenates were denatured at 95 1C for 3 min in Laemmli buffer.
Samples were subjected to sodium dodecyl sulfate–polyacrylamide
gel electrophoresis in 10% polyacrylamide gels. After electrophor-
esis, proteins were electrotransferred to a polyvinylidene difluoride
membrane (Bio-Rad, Hercules, CA, USA), which was incubated in
blocking buffer (5% milk, 20 mM Tris-HCl, pH 7.4, 150 mM NaCl,
0.05% Tween 20) at 4 1C for 1 h and then incubated with anti-NOS-
1 antibody (1:200, sc-5302; Santa Cruz Biotechnology, Santa Cruz,
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CA, USA), anti-NOS2 (1:200, sc-650; Santa Cruz Biotechnology),
and anti-NOS-3 antibody (1:250, 610296; BD Transduction
Laboratories, San Diego, CA, USA) overnight. Binding of the
primary antibody was detected by an enhanced chemiluminescence
method (ECL Plus; GE Healthcare Biosciences, Piscataway, NJ, USA)
using horseradish peroxidase-conjugated secondary antibodies (goat
anti-mouse immunoglobulin G 1:5000 sc-2031, goat anti-rabbit
immunoglobulin G, 1:5000, sc-2030; Santa Cruz Biotechnology).
The blot membrane was then stripped by incubating in 1.2 M glycine
(pH 2) for 2 h and used for additional protein expression
detection. Quantification of protein expression was performed
using Gel-ProAnalyzer (Media Cybernetics, Silver Spring, MD,
USA).
Statistical analysis
Results were presented as mean±s.e. Differences between groups
were analyzed by one-way analysis of variance and differences before
and after drug administration were analyzed by two-way repeated-
measures analysis of variance, using statistic software SPSS.
Statistical significance was taken at Po0.05.
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